Trial Profile
Testing the Ability of Immunotherapy to Alter the Tumor Immune MicroEnvionment (TIME) and Reduce or Eradicate High Risk DCIS
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs MRNA 2752 (Primary) ; Pembrolizumab (Primary)
- Indications Ductal carcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Sep 2023 Planned number of patients changed from 48 to 68.
- 21 Oct 2022 Planned End Date changed from 30 Jun 2023 to 31 Mar 2024.
- 21 Oct 2022 Planned primary completion date changed from 30 Jun 2023 to 31 Mar 2024.